Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003302 | 0.86 | CTSA (0.39) | ALOX5APFEN1SQORCTSAPIK3CA | |
| SCHEMBL2004116 | 0.83 | FFAR4 (0.46) | CITCTSANR3C1SCN9APGR | |
| SCHEMBL27780041 | 0.83 | FFAR4 (0.46) | CITCTSANR3C1SCN9APGR | |
| SCHEMBL2002894 | 0.79 | ADRB2 (0.42) | CITGPBAR1 | |
| SCHEMBL2003919 | 0.79 | ADRB2 (0.42) | CITGPBAR1 | |
| SCHEMBL2005877 | 0.78 | TAAR1 (0.41) | SQORCTSAGRM7 | |
| SCHEMBL2006367 | 0.76 | TNF (0.38) | SQORCTSANR3C1 | |
| SCHEMBL22996519 | 0.75 | MAP4K1 (0.38) | PIK3CAMTORSCN9AP2RX3P2RX2 | |
| SCHEMBL18361541 | 0.75 | MAP4K1 (0.38) | PIK3CAMTORSCN9AP2RX3P2RX2 | |
| SCHEMBL29167804 | 0.75 | MAP4K1 (0.38) | PIK3CAMTORSCN9AP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | CIT 3115/4885ALOX5AP 1784/4885FEN1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.